- Previous Close
2.5800 - Open
2.5800 - Bid 2.5600 x --
- Ask 2.6600 x --
- Day's Range
2.5400 - 2.8000 - 52 Week Range
0.9953 - 4.0300 - Volume
496,281 - Avg. Volume
297,856 - Market Cap (intraday)
194.423M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.
www.nextcellpharma.comRecent News: NXTCL.ST
View MorePerformance Overview: NXTCL.ST
Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NXTCL.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NXTCL.ST
View MoreValuation Measures
Market Cap
194.42M
Enterprise Value
147.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.23
Price/Book (mrq)
2.88
Enterprise Value/Revenue
13.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.72%
Return on Equity (ttm)
-58.55%
Revenue (ttm)
11.28M
Net Income Avi to Common (ttm)
-41.96M
Diluted EPS (ttm)
-0.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
46.79M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-22.93M